Digest Network Come funziona
Network
/
Società
Ta
Non verificato

Takeda Pharmaceutical Company Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

68 comunicati stampa

Guarda tutti i comunicati
29/10/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Titoli e azioni
Eventi
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Vetrine/Shopping
Medicina - Varie
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
23/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
19/10/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Industria
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
15/10/2026
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
14/10/2026
Farmaceutica
Salute
Medicina - Varie
Eventi
Fiere
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
30/09/2026
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
22/09/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
18/09/2026
Sanità
Associazioni/Professionisti
Farmaceutica
Ecologia/Salute ambientale
Biotecnologia
Salute
Mercato del lavoro
Responsabilità sociale d'impresa
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
14/09/2026
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
09/09/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0